SCHEMBL13289317

SCHEMBL13289317

Bc1cnn2c(NCCNS(=O)(=O)c3ccccc3C(F)(F)F)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.43
▸ GSK3B P49841 5/20 0.41
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ GFER P55789 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CLK1 P49759 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PTGES O14684 1/20 0.35
▸ CCR1 P32246 1/20 0.35
▸ SLC22A12 Q96S37 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13288926 0.95 CDK2 (0.42) CDK2GSK3BHTTSMN1; SMN2GFER
SCHEMBL13121293 0.90 CDK2 (0.55) CDK2GSK3BGFER
SCHEMBL14546009 0.90 CDK2 (0.46) CDK2GSK3BSMN1; SMN2MAPTALDH1A1
SCHEMBL13289547 0.89 CDK2 (0.46) CDK2GSK3BSMN1; SMN2CCR1
SCHEMBL12954317 0.87 GSK3B (0.45) CDK2GSK3BMAPTALDH1A1LMNA
SCHEMBL13289569 0.87 CDK2 (0.51) CDK2GSK3B
SCHEMBL13289063 0.87 GSK3B (0.45) CDK2GSK3BHTTCCR1ALDH1A1
SCHEMBL13289128 0.85 CDK2 (0.44) CDK2GSK3BMAPTCCR1ALDH1A1
SCHEMBL13288981 0.85 CDK2 (0.46) CDK2GSK3BSMN1; SMN2GFERMAPT
SCHEMBL13289301 0.85 CDK2 (0.46) CDK2GSK3BGFERMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback